Short-term selling pressure weighs on Novo Nordisk stock, sending it down 3.88%

Traders Union
All News
Financial News
Novo Nordisk drops 3.88% despite positive news

Highlights

Novo Nordisk will repurchase up to DKK 11.2 billion in shares as part of its ongoing DKK 15 billion buyback program through early 2027.
Positive new clinical data were presented for next-generation diabetes and obesity therapies, with CagriSema meeting all primary and secondary endpoints in Phase 3 trials.
Shares trade under persistent selling pressure with a bearish momentum bias, with an expected short-term range of $39.59 to $42.61 and downside risk dominant.

Share buyback, drug progress signal optimism amid persistent selling

Novo Nordisk announced on June 8, 2026, that it would continue executing its DKK 15 billion share buyback program, scheduling DKK 11.2 billion in B share repurchases between May 6, 2026, and February 1, 2027, as its treasury shareholding reached 0.8%. The company also presented new clinical data for its next-generation diabetes therapies at the American Diabetes Association conference, reported that oral Wegovy prescriptions had reached 3 million, and disclosed that Phase 3 Reimagine trials for the experimental obesity drug CagriSema met both primary and secondary endpoints for efficacy. These developments reflect ongoing capital return activities and positive drug pipeline progress, though price action has remained under broader selling pressure.

Oversold signals and resistance cap price amid strong sell momentum

NVO closed below the MA-20 ($42.85), MA-50 ($43.42), and MA-200 ($48.66) thresholds, with the Ichimoku Kijun line at $42.69 marking immediate resistance. Momentum indicators are negative, as both the MACD and ADX indicate ongoing selling. Oversold readings are registered across the RSI, Stoch RSI, and CCI, while BBP and the Awesome Oscillator both affirm short-term seller dominance and the prevailing downtrend. The session ended with high volatility and a closing price near the daily low, reinforcing the unfavorable technical posture.

Range-bound outlook as downside risk outweighs rebound potential

In the short term, the likely price range is projected between $39.59 and $42.61, aligning with recent volatility. Statistical probabilities suggest a 22% chance of a rebound and a 78% likelihood of continued downside. Base case expectations favor near-term consolidation within this band, while a sustained move above $42.69 would be required to trigger a bullish shift. Should support at $39.59 break, the probability of further declines increases.

Viktoras Karapetjanc, analyst at Traders Union, sees Novo Nordisk supported by robust fundamentals and steady capital returns. He believes the ongoing buyback and strong diabetes pipeline offset the current technical weakness. Near-term consolidation is likely as the price stabilizes, and renewed upside requires a break above key resistance. "The market is discounting positive fundamentals for now, but constructive sentiment could return quickly on a technical reversal."

Previously it was reported that Novo Nordisk and Eli Lilly intensified their rivalry in the obesity drug market as prescription momentum and pipeline advances drove investor optimism. In light of the recent technical breakdown in NVO shares despite continued progress on drug development and share buybacks, traders should closely watch for a decisive move above $42.69 to signal reversal potential amid the prevailing negative momentum.

Source of Data: NVO Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.